Its resistance mechanisms involve CD38 downregulation coupled with upregulation of complement inhibitors CD55 and CD59.[12] Future investigations should prioritize developing targeted therapies against CDK6, CD38, CD55, and CD59, potentially unveiling novel strategies to overcome tumor drug resistance. The gene discussed is CDK6; the disease is neoplasm.